Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Amongst sufferers within the relapsed/refractory and treatment-naive settings with Bruton tyrosine kinase inhibitor–naive persistent lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), Jaypirca...
Jaypirca (pirtobrutinib) was discovered to have related efficacy as Imbruvica (ibrutinib) in enhancing medical efficacy in sufferers with persistent lymphocytic leukemia (CLL)...
